Dapsone has been part of the World Health Organization multidrug therapy for the treatment of leprosy. While it has been efficacious in the management of leprosy, there are many patients who develop adverse drug reactions to the drug including life-threatening reactions such as dapsone hypersensitivity syndrome (DHS). We report a case of a patient who was prescribed dapsone as part of multidrug therapy for leprosy following which she developed DHS. Her condition worsened after tapering the oral steroids given to manage the DHS, and she was detected to have hypothyroidism. She developed diabetes mellitus and succumbed to septic shock.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830851 | PMC |
| http://dx.doi.org/10.4103/ijp.IJP_764_16 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dapsone Hypersensitivity Syndrome Skin Rash Exhibiting Anatopic Phenomenon.
Indian Dermatol Online J
August 2024
Department of Dermatology, Venereology and Leprosy, Sri Manakula Vinayagar Medical College and Hospital, Pondicherry, India.
A retrospective cohort study of monthly rifampicin, ofloxacin and minocycline in the management of leprosy at the Hospital for Tropical Diseases, London, United Kingdom.
PLoS Negl Trop Dis
December 2024
Hospital for Tropical Diseases, University College London Hospitals NHS Foundation Trust, London, United Kingdom.
Introduction: The World Health Organization (WHO) recommends rifampicin, dapsone and clofazimine multi-drug therapy (MDT) for the treatment of leprosy. Severe adverse effects include dapsone hypersensitivity syndrome, skin pigmentation, haemolytic anaemia, and hepatitis. At the Hospital for Tropical Diseases (HTD), London, United Kingdom monthly rifampicin, ofloxacin and minocycline (mROM) is used as first line treatment for leprosy.
View Article and Find Full Text PDFUrticarial vasculitis.
Curr Opin Rheumatol
January 2025
Marmara University School of Medicine, Department of Dermatology, Istanbul, Türkiye.
Article Synopsis
- Urticarial vasculitis (UV) is a rare condition that can range from mild skin issues to serious systemic problems, and recent research focuses on its causes, diagnosis, and treatment options.
- New triggers for UV associated with SARS-CoV-2 and COVID-19 vaccines have been noted, along with a new clinical-dermoscopic method for diagnosis that reduces reliance on skin biopsies.
- Treatments such as antihistamines, corticosteroids, and rituximab show promise for success and long-lasting remission, while epidemiological studies show good survival rates but highlight certain severe health issues that can increase mortality.
Managing Urticarial Vasculitis: A Clinical Decision-Making Algorithm Based on Expert Consensus.
Am J Clin Dermatol
January 2025
Institute of Allergology, Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Hindenburgdamm 27, 12203, Berlin, Germany.
Urticarial vasculitis (UV) is a rare and difficult-to-treat, small-vessel leukocytoclastic vasculitis presenting with recurrent long-lasting wheals. So far, no guidelines and treatment algorithms exist that could help clinicians with the management of UV. In this review, we describe evidence on systemic treatments used for UV and propose a clinical decision-making algorithm for UV management based on the Urticarial Vasculitis Activity Score assessed for 7 days (UVAS7).
View Article and Find Full Text PDFFeedback regulation of VISTA and Treg by TNF-α controls T cell responses in drug allergy.
Allergy
November 2024
Hospital for Skin Diseases, Shandong First Medical University, Jinan, Shandong, China.
Background: Severe cutaneous adverse reactions (SCARs) mediated by cytotoxic T lymphocytes are a series of life-threatening conditions with a mortality of 4%-20%. The clinical application of tumor necrosis factor-alpha (TNF-α) antagonist improves the outcome of some SCARs patients; however, this is complicated by the elusive and varied immunopathogenesis.
Aim: To investigate whether IgE antibody responses to HEMAs are associated with AD, its severity, and response to dupilumab.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!